Valuation: Black Diamond Therapeutics, Inc.

Market Cap 115M 101M 92.73M 86.01M 164M 10.99B 166M 1.11B 431M 5.39B 432M 423M 18.67B P/E 2026 *
-3.1x
P/E 2027 * -2x
Enterprise Value 115M 101M 92.73M 86.01M 164M 10.99B 166M 1.11B 431M 5.39B 432M 423M 18.67B EV / Sales 2026 *
20.7x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day-1.99%
1 week+15.20%
Current month+6.49%
3 months-17.57%
6 months-23.35%
Current year-18.93%
1 week 1.74
Extreme 1.745
2.07
1 month 1.6
Extreme 1.6
2.07
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
12
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 51 10/08/2021
Chief Executive Officer 62 15/09/2023
Director of Finance/CFO 41 06/10/2024
Director TitleAgeSince
Director/Board Member 61 28/02/2017
Director/Board Member 47 30/11/2019
Director/Board Member 50 30/11/2018
Date Insider Type Main position Quantity % Market Cap.
06-25Free

Director

40,000 0.0698%
06-25Free

Director

40,000 0.0698%
06-25Free

Director

40,000 0.0698%
Change 5-day change 1-year change 3-year change Capi.($)
-1.99%+15.20%-23.64%-59.47% 115M
-2.14%+3.65%+74.05%+131.89% 59.1B
-0.93%+4.05%+73.64%+90.53% 55.19B
-3.71%+2.97%-14.61%-13.89% 24.67B
-0.05%+7.89%+14.05%+440.15% 24.19B
+0.64%+14.41%+44.27%-3.20% 19.69B
-2.19%+7.37%+40.74%-30.67% 17.56B
+3.58%+25.11%+196.41%+363.46% 16.22B
+4.91%+25.24%+44.61% - 14.84B
-0.57%+1.39%+20.33%+191.65% 14.04B
Average -0.24%+9.37%+46.98%+123.38% 24.56B
Weighted average by Cap. -0.71%+6.43%+57.56%+134.65%

Financials

2026 *2027 *
Net sales 5.56M 4.85M 4.47M 4.15M 7.89M 530M 7.99M 53.37M 20.8M 260M 20.86M 20.4M 900M -
Net income -40.47M -35.37M -32.58M -30.22M -57.49M -3.86B -58.18M -389M -152M -1.89B -152M -149M -6.56B -70.04M -61.21M -56.39M -52.31M -99.49M -6.68B -101M -673M -262M -3.28B -263M -257M -11.35B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
06/07/26 US$1.970 -1.99% 1,787,745
02/07/26 US$2.010 +9.24% 1,577,070
01/07/26 US$1.840 -0.54% 4,375,137
30/06/26 US$1.850 +5.71% 1,883,436
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.970USD
Average target price
9.857USD
Spread / Average Target
+400.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock